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Abstract
Background—Small intestinal bacterial overgrowth (SIBO) has been implicated in the
pathogenesis of irritable bowel syndrome (IBS), although with significant controversy.
Aims—To determine the prevalence of SIBO in IBS and its association with colonic motility,
bowel symptoms and psychological distress.
Methods: Sucrose hydrogen and methane breath tests were performed in 158 IBS and 34 healthy
controls (HC). Thresholds for pain and urgency were tested by barostat in the descending colon.
The motility index (MI) was calculated as the average area under the curve for all phasic
contractions. Questionnaires assessed psychological distress, IBS symptom severity (IBSSS), IBS
Quality of Life (IBS-QOL) and self reported bowel symptoms.
Results: 52/158 (32.9%) IBS patients had abnormal breath tests compared with 6/34 (17.9%) HC
(χ2=0.079). SIBO (SIBO+) and Non-SIBO (SIBO−) did not differ in the prevalence of IBS-
subtypes, IBS-SS, IBS-QOL and psychological distress variables. IBS had a greater post-
distension increase in MI than HC, but there was no difference between SIBO+ and SIBO−.
Predominant methane producers had higher urge thresholds (28.4 vs. 18.3, p<0.05) and higher
baseline MI (461 vs. 301.45, p<0.05) than SIBO− IBS, and they reported more “hard or lumpy
stools” when compared to predominant hydrogen producers (p<0.05) and SIBO− IBS (p< 0.05).
Conclusions: SIBO is unlikely to contribute significantly in the pathogenesis of IBS. Methane
production is associated with constipation.
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Small Intestinal bacterial overgrowth (SIBO) is characterized by the presence of an
abnormally high number of bacteria in the small bowel. SIBO may be associated with a
broad range of predisposing conditions including decreased peristaltic motility in the small
intestine or surgical procedures that encourage stasis(1;2). The usual symptoms are diarrhea,
flatulence, abdominal pain and bloating(3). SIBO has been proposed to be common in IBS
with reported prevalence figures ranging from 10-70%(4;5). Galatola et al(6) showed that
29% of IBS patients without diarrhea, and 56% of those with diarrhea of obscure origin had
an abnormal 1g-14C Xylose breath test. However, Pimentel et al reported a prevalence of
80% among IBS patients, and suggested (a) that SIBO may be the etiology for all or most
IBS, and (b) that antibiotics are an effective treatment for IBS(5). However, these assertions
are controversial(7). Critics have suggested that differences in how SIBO is diagnosed, and
especially differences in which substrate is used, may account for inconsistencies between
studies.
Early studies of SIBO tested only for excess hydrogen in breath following ingestion of
sugar, and those studies usually reported diarrhea to be the primary symptom. However,
recent studies also test for elevated methane and find that this gas, which is liberated by
anaerobic bacteria, is more often associated with constipation. Pimentel et al showed in
animal studies that exogenous methane slows transit and augments non-propagating
contractions in the small bowel(8). Further work is needed to evaluate methane’s effect on
colonic motility and its association with constipation.
Pimentel et al and others recommend that IBS be treated with broad spectrum antibiotics(9).
However, treatment with antibiotic is not completely safe: antibiotics may worsen symptoms
of IBS by altering the delicate balance of “good” and “bad” (e.g., probiotic vs. harmful)
bacteria in the gut(10). Whether antibiotic choices should differ for patients who are
predominant hydrogen vs. predominant methane producers remains to be determined.
No study has looked at psychological distress as a moderating variable in SIBO patients.
However, some studies showed increased prevalence of positive breath tests in fibromyalgia
patients which may indicate an association between psychological distress factors like
somatization and SIBO(11).
The aims of this study were: (a) Determine the prevalence of SIBO in a large sample of
patients with IBS and in controls. (b) Compare IBS patients with and without SIBO for
differences in clinical symptoms and physiological and psychological variables. Clinical
parameters tested were IBS subtype, IBS quality of life, and IBS symptom severity.
Physiological variables studied were pain and urge thresholds, and phasic contractions under
conditions of fasting, response to intraluminal distension, and response to a high fat meal.
Psychological variables studied were anxiety, depression and somatization. (c) Subdivide
IBS patients with SIBO into predominant methane producers (PMP) and predominant
hydrogen producers (PHP) and compare these groups with respect to predominant IBS
subtype, IBS symptom severity and quality of life impact, pain and urge thresholds, and
phasic contractions of the descending colon.
METHODS
Subjects
Subjects were recruited by advertisement or physician referrals and screened by telephone.
The study population consisted of 158 patients with physician diagnoses of IBS confirmed
by Rome II criteria. Rome II criteria require abdominal pain or discomfort at least 25% of
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weeks plus 2 or more of the following: (1) relief of pain or discomfort with defecation; (2)
onset of discomfort associated with a change in frequency of stool; and/or (3) onset of
discomfort associated with a change in form (appearance) of stool(12). These subjects had
no history of gastrointestinal resection (other than appendectomy, or cholecystectomy),
inflammatory bowel disease, heart disease or diabetes mellitus, and they were not pregnant
at the time of study.
The control population consisted of 34 subjects without any significant gastrointestinal
problems. Exclusion criteria were average stool frequency less than 3/week or more than 3/
day, abdominal pain or use of a laxative or anti-diarrheal agent on more than two occasions
over the prior year, history of alcohol or substance abuse, a psychiatric diagnosis, or any of
the medical conditions listed above for the IBS patients. The study was approved by the
Institutional Review Board of the University of North Carolina (UNC) and all subjects
provided written informed consent prior to participation.
Study design
Subjects were admitted to the General Clinical Research Center for a 24-30 hour period.
They were asked to fast for at least 4 hours prior to admission. On the day of admission, a
medical history, physical examination, and hydrogen breath test (HBT) for SIBO were
performed. The symptom severity scale, quality of life scale, and psychological
questionnaires were completed during the breath test. At the end of day 1, bowel preparation
for next day’s procedure with 1.5 oz of Fleet’s phosphosoda repeated twice, was performed.
On day 2 physiological testing were performed (see colonic sensory and motor testing
below).
Questionnaires
The Irritable Bowel Syndrome Quality of Life Scale(13) (IBS-QOL) is a validated, disease-
specific scale to measure the impact of IBS symptoms on quality of life. It is a 34-item self-
report questionnaire with 8 subscales: dysphoria, interference with activity, body image,
health worry, food avoidance, social reaction and sexual relationship. Subjects are asked to
answer questions about their feelings over the past 30 days on an ordinal scale (1-“not at all”
to 5-“a great deal”).
The Irritable Bowel Severity Scoring System(14) (IBS-SS) is a validated scale for
measuring the overall severity of IBS symptoms. It consists of 5 equally weighted questions
about symptoms occurring in the past 10 days: the average intensity of abdominal pain, the
number of days with any abdominal pain, the average severity of abdominal distension,
dissatisfaction with bowel habits, and the degree to which bowel symptoms interfered with
usual activities. Responses to all except the pain frequency question were on a 0-100
numeric scale (“none” to “worst ever”), and the number of days of pain in the past 10 days
was multiplied by 10 to arrive at a 0-100 score for this item. The scores on these 5 questions
were added to arrive a total score of 0-500.
The Brief Symptom Inventory-18(15) (BSI-18) is a validated questionnaire for measuring
the degree of psychological distress over the past week. Subjects are asked how much they
were bothered by each of 18 symptoms, and they respond on a 5-point ordinal scale (“not
bothered at all” to “extremely bothered”). The BSI includes three subscales - anxiety,
depression and somatization - and a global symptom index (GSI) scale. Sum scores of each
subscale and the GSI were converted to standardized scores where the mean for the healthy
population is a score of 50 and each standard deviation from the mean is equal to 10 scale
points; thus a score of 60 is one standard deviation above the mean. These standardized
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scores adjust for sex differences in the reporting of psychological symptoms, so that BSI-18
scores for males and females can be pooled together.
The Recent Physical Symptom Questionnaire(16) (RPSQ) is an IBS-specific somatization
scale. It consists of 26 items to which subjects respond on a 5-point frequency scale
describing how often each symptom occurred in the last month. The Catastrophizing
Scale(17) measures negative self-statements and catastrophizing thoughts related to pain.
Subjective assessment of bowel patterns was also done by means of questions adopted from
the Rome III modular questionnaire(18) – “In last three months how often did you have:
Less than 3 bowel movements (BM) (0-2) in a week, More than 3 BM (≥4) in a day, Hard or
lumpy stools, or Loose, mushy or watery stools.
Equipment
The barostat is a computer-controlled pump (Distender II model, G&J Electronics,
Willodale, Ontario, Canada) used for testing sensory thresholds in the gut lumen. It inflates a
plastic bag to a predefined pressure and holds this pressure constant for a fixed period of
time by adding or subtracting air at 38 ml/sec. Volumes and pressures are recorded 16 times
per second and are displayed graphically in real time.
The motility catheter (Model C7-CB-0026, Mui Scientific, Mississauga, Ontario, Canada) is
5 mm wide bundle of smaller polyethylene tubes bonded together. It includes a central
lumen which accommodates a guide wire, 2 lumens which open inside the bag (one to
inflate/deflate the bag and a second to monitor pressure inside the bag), plus 4 small
catheters used to measure pressures 2.5 and 5 cm from the proximal and distal edges of the
bag. A disposable, 10 cm long, 600 ml capacity polyethylene bag (Model CT-BP600R, Mui
Scientific) was attached to the surface of the motility catheter.
The pneumohydraulic pump (8 channel hydraulic capillary infusion system, Arndorfer Inc,
Greendale, Wisconsin) uses a tank of compressed air to force de-gassed sterile water from a
reservoir through 4 capillary catheters which are connected to 4 pressure transducers. These
pressure transducers are also connected to the 4 small catheters in the motility catheter
which open above and below the barostat bag. Water is perfused through the pressure
transducers and the perfusion catheters at a rate of 0.37 ml/min. A continuous column of
water connecting the pressure transducer to the openings on the outside of the motility
catheter allows transmission of pressure changes occurring at the catheter openings to the
pressure transducers. The outputs of these pressure transducers were continuously recorded
(see below).
A physiological recorder [Synectics Polygram (Medtronic Inc., Minneapolis, MN)] was used
to record phasic motility changes above and below the balloon and store them in a digital
file. A research nurse marked these recordings to indicate which experimental condition was
in effect.
Colonic sensory and motility testing
All physiological and sensory testing was performed on Day 2. A flexible sigmoidoscope
was used to guide placement of barostat catheter over the guide wire in the descending colon
and the position was confirmed by fluoroscopy. Following this, the subject rested for 90 min
before testing began. No sedation was used during sigmoidoscopy. Subjects were not
permitted to have food until the test meal.
Sample distention and determination of individual operating pressure—
Subjects were instructed to give separate ratings of the intensity of pain and urgency to
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defecate experienced at the end of each distention, using a six point scale (0= no sensation; 1
= weak; 2= mild; 3 = moderate; 4 = strong; 5 = intense). The scale was visible to subjects
during the procedure. Sample distensions were then performed during which the barostat
bag was inflated in a stepwise fashion by increasing pressure by 4 mmHg every 15 seconds
until the subject reported moderate pain (rating of 3). These distensions were done to: (a) to
insure that the barostat bag was unfolded; (b) to teach the subject how to use the rating scale;
and (c) to lower anticipatory anxiety. The barostat bag was then slowly inflated with 30 ml
of air and the pressure was allowed to equilibrate for 3 minutes. The average bag pressure
during the last 15 seconds defined the individual operating pressure (IOP)(19), which is the
minimum pressure required to overcome mechanical forces and inflate the bag with 30 ml of
air. All sensory and motility testing was done with the subject in prone position to avoid
overlying body tissues compressing the bowel.
Ascending method of limits (AML)—Pain thresholds in the colon were assessed using
the AML (19). Phasic distensions were 30-sec long separated by 30 sec rest intervals starting
at the IOP and progressively increasing in 2 mmHg steps until either the subject requested
the research nurse to stop the protocol or 48 mmHg was reached. The pain threshold was
defined as the amount of pressure above the IOP at which the subject first reported moderate
pain (absolute distending pressure minus the IOP). If the subject reached 48 mmHg without
reporting moderate pain, then the pain threshold was defined as 50 mmHg minus the IOP.
After measuring pain thresholds, there was a 15 min rest period.
Colonic phasic motility—Phasic contractions were measured from the perfusion ports
above and below the bag under the following conditions: (a) during fasting baseline for 10
min at the IOP, (b) during distention for 10 min at a pressure of IOP+20 mmHg, (c) during a
recovery period after intraluminal distention for 15 min at the IOP, and (d) following the
meal for 30 min at the IOP. These tracings were visually screened to exclude artifacts (i.e.,
wave amplitudes < 5 mmHg or durations < 6 sec). The beginning and ending inflection
points for each individual contraction were identified visually and the area under the curve
was calculated using computer software (Polygram, Lower GI Edition, Version 5.06;
Synectics Medical, now Medtronic, Inc., Minneapolis, MN). These areas were added
together, then divided by recording time in secs (excluding the time occupied by movement
artifact), and multiplied by 100. The motility index (MI) was the average of phasic
contractions at 4 perfusion ports.
Postprandial motility—The standardized test meal contained 810 kcals and 38 grams of
fat to be consumed within 10 minutes. Immediately after completing the meal, the patient
returned to the prone position and bag pressure was maintained at the IOP for 30 min (the
post-prandial period). Phasic motility was recorded throughout this period.
Hydrogen Breath Test (HBT)
To minimize basal hydrogen production, subjects were asked to have carbohydrate restricted
dinner a day before and fasted overnight prior to the HBT. Smoking and physical exercise
were not allowed 2 hours prior to and during the test. A baseline endexpiratory breath
sample was obtained prior to ingestion of 50 gm of sucrose (dissolved in 250 ml of water).
Additional breath samples were obtained every 15 minutes for 2 hours. The samples were
analyzed for hydrogen and methane concentrations in parts per million (ppm) using a
Quintron microanalyzer (Quintron Instrument Company, Milwaukee, USA). Breath tests
were considered to indicate SIBO based on the following criteria(20).
1. A baseline breath hydrogen of ≥20 parts per million (ppm) (Elevated methane at
baseline was not interpreted as evidence of SIBO because this most likely reflects
colonic bacterial fermentation.).
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2. An increase of breath hydrogen and/or methane of ≥12 ppm above the baseline that
occurs within the first 60 minutes.
3. If the first peak (≥12 above baseline) occurs more then 60 minutes after ingestion
of sucrose and is followed by a second peak after a gap of at least 15 minutes. The
second peak should be ≥20 ppm above the baseline and should be clearly separated
by a dip in concentration from the first peak.
IBS subjects with a positive breath test were further subdivided into predominantly
hydrogen producers (PHP) and predominantly methane producers (PMP) based on whether
changes in hydrogen or methane were used to diagnose SIBO. Since criteria 1 involves only
hydrogen, SIBO diagnosed with that criteria were classified as PHP.
Data and statistical analysis
Residual plots of all data sets were examined to decide whether parametric or non-
parametric procedures were appropriate. Summary statistics of normally distributed data are
expressed as means and standard deviations (SD). Student-t tests were used to compare the
groups. Analysis of variance was performed if more than two groups were compared. For all
analysis a p-value of <0.05 without adjustment for multiple comparisons defined statistical
significance. Categorical data were analyzed using chi-square test with continuity
correction.
RESULTS
One hundred fifty eight IBS patients (25 males; mean age 34.6 years) and 34 healthy
controls (HC) (8 males; 37.2 years) underwent colonic sensory, motility studies and
hydrogen breath testing. Table 1 shows demographic characteristics of the sample. There
were no significant differences between IBS patients and HC in gender, age, or race.
IBS vs. Health Controls
The prevalence of SIBO was 32.9% in IBS (52/158) and 17.9% (6/34) in HC (Pearson
χ2=0.079). In IBS subjects who were diagnosed as SIBO, 48.0% (25/52) fulfilled criteria 1
for diagnosis, 46.2% (24/52) criteria 2, and 5.8% (3/52) criteria 3 [See Hydrogen Breath
Test above]. In controls 50% (3/6) were diagnosed with SIBO with both criteria 1 and 2.
Overall, 48.3% (28/58) of SIBO was diagnosed using criteria 1, 46.5% (27/58) using criteria
2 and 5.2% (3/58) using criteria 3.
The sample size of IBS (158) vs. HC (34) achieved 74% power and sample size of SIBO+
(52) vs. SIBO− (106) achieved 84% power to detect 0.5 standard deviation with a
significance level (alpha) of 0.05 using a two-sided t-test.
SIBO-IBS vs. Non-SIBO IBS
Clinical symptoms—The distribution of IBS subtypes in the SIBO+ population was
30.8% IBS-D, 30.8% IBS-C, and 38.5% IBS-M; and in the SIBO− group there were 29.2%
IBS-D, 25.5% IBS-C, and 45.3% IBS-M. There were no significant differences in the
prevalence of various IBS subtypes in SIBO+ or SIBO− IBS populations.
IBS patients scored significantly higher than HC on the IBS-SS. However, there were no
significant differences between SIBO+ and SIBO− patients on the IBS-SS. Both SIBO+ and
SIBO− IBS groups scored lower on the IBS-QOL than HC, but there were no significant
differences between these two groups (Table 1).
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Psychological determinants—As shown in Table 1, IBS patients scored significantly
higher than HC on all subscales of the BSI-18. SIBO+ IBS trended to score higher than
SIBO− IBS patients on the global symptom index and somatization subscale (p<0.10), but
this did not achieve statistical significance. There were no significant differences on the
RPSQ or the Catastrophizing Scale between SIBO+ and SIBO− IBS patients; however, both
scored significantly higher than HC (Table 1).
Physiological parameters—SIBO+ and SIBO− IBS groups had lower AML pain
thresholds (IOP corrected) compared to HC (Table 2). There were no significant differences
between SIBO+ and SIBO− IBS groups, although there was a trend (p<0.10) favoring lower
pain thresholds in SIBO− compared to SIBO+ subjects. SIBO+ and SIBO− patients also had
significantly lower urge thresholds compared to HC, but there was no statistically significant
difference between the SIBO+ and SIBO− IBS groups.
Phasic Colonic motility—There was no difference in the MI (phasic contractions) at
baseline (fasting, no intraluminal distension) between SIBO+ and SIBO− IBS subjects and
none when compared with HC (Table 2). In response to intraluminal distension, both IBS
and HC showed a significant increase in phasic contraction compared to their respective
baselines; this is referred to in Table 2 as reactivity. Reactivity was greater in both SIBO+
and SIBO− IBS patients compared to HC (P<0.05), but there were no significant differences
in reactivity between SIBO+ and SIBO− IBS groups. During the recovery period following
intraluminal distension, the MI declined nearly to baseline levels in all groups. The SIBO+
group showed a higher MI during recovery than HC but was not significantly different from
SIBO− IBS. All groups showed significant increases in MI following the meal, but the
magnitude of meal stimulated increase was not different in IBS vs. HC nor was there a
significant difference between SIBO+ and SIBO− IBS groups (Table 2).
Predominant Hydrogen Producers vs. Predominant Methane Producers
The distribution of bowel habit subtypes in PHP was 38.1% IBS-D, 23.8% IBSC, and 38.1%
IBS-M compared in PMP to 0% IBS-D, 60% IBS-C, and 40% IBS-M. There were no
significant differences among PHP, PMP, and SIBO− IBS patients in the IBS-SS total score
or individual symptoms (Table 3).
As shown in Table 4, AML pain thresholds were similar among PMP, PHP and SIBO− IBS
patients. However, the AML urge threshold was higher in PMP than in SIBO− IBS, which is
in keeping with this being a predominantly constipated group.
Motility Indices
As shown in Table 4, the baseline MI was significantly higher in PMP patients compared to
SIBO− IBS patients. However, PHP and PMP were not significantly different from each
other during baseline, intraluminal distention, recovery from distention, or the post-prandial
period.
Bowel pattern
As shown in Table 5, PMP subjects were significantly more likely to report hard or lumpy
stools compared to PHP and SIBO− IBS patients. There was also a trend for PMP to report
more often that their bowel movements occurred less than 3 times per week compared to
PHP and SIBO− IBS (p=0.055). Self-described bowel habits in the PHP group did not
appear to differ from those in the SIBO− IBS group.
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Relationship between gas production and IBS-SS
The IBS-SS scale was not significantly correlated with peak levels of hydrogen in the PHP
group (rho=-0.06) or with peak methane production in the PMP group (rho= −0.11).
Similarly, the IBS-SS was not significantly correlated with the area under the curve for
hydrogen in PHP patients or with area under the curve for methane in the PMP group.
DISCUSSION
These data fail to confirm that the prevalence of SIBO is higher in IBS (32.9%) compared to
HC (17.9%), although there was a trend in this direction (p=.079). We also observed a lower
prevalence of SIBO in our IBS population as compared to some other studies, probably due
to differences in the assessment method and criteria used to define SIBO(21).
We used sucrose as the substrate for HBT which has advantages over popularly used
lactulose. Sucrose is broken down into glucose and fructose. Glucose is completely absorbed
in the small intestine and fructose is also absorbed through GLUT-5 mediated transport in
the jejunum. The glucose breath test is more specific (78-83% vs. 44-70%) and more
sensitive (62-93% vs. 17-68%) than the lactulose breath test(2;22). Consequently any peak
in hydrogen and methane after sucrose ingestion is considered diagnostic of SIBO. However
with lactulose, because it is not absorbed in the small intestine, the timing and amplitude of
the peaks (small intestinal vs. colonic) have to be considered, which reduces the inter-
observer agreement from a κ value of 1.0 (with glucose) to 0.86(20). A disadvantage of
sucrose (used in our study) is that there can be a delayed peak in hydrogen or methane due
to either sucrose malabsorption as seen individuals with sucrase deficiency(23;24) or rarely
in fructose malabsorption(25;26). However, fructose in the form of sucrose is better
absorbed because of facilitation by glucose(27). Hence, it makes it important to differentiate
a second colonic peak to prevent misdiagnosing sucrose or fructose intolerance as SIBO.
However, sucrose is unlike lactulose, which will always have a colonic peak that needs to be
separated from small intestinal peak and that may give a higher number of false positives.
This is evident by the fact that only 5.2% (3/58) of total SIBO population was diagnosed
using the double peak criteria (criteria 3: See Hydrogen Breath Testing above) in our study.
The second goal of our study was to compare SIBO+ IBS patients to SIBO− IBS patients to
determine whether SIBO is associated with specific bowel symptoms and specific
physiological mechanisms. Although diarrhea is often regarded as the hallmark symptom of
SIBO(3), we found no differences between SIBO+ and SIBO− IBS patients in the
proportion who met criteria for IBS-D (30.8% vs. 29.2% respectively). However, with the
recent recognition of methane in SIBO and its association with constipation, the association
of SIBO with only diarrheal symptoms has already being questioned(28). Another symptom
frequently thought to be associated with SIBO is bloating and distention. However, SIBO+
did not differ from SIBO− IBS patients on the abdominal distention scale of the IBS-SS
(46.8 vs. 49.9 respectively), nor did they differ in overall IBS-SS (272.9 vs. 278.4
respectively).
Our IBS patients scored significantly higher on psychological distress variables including
anxiety, depression, somatization and catastrophizing compared to HC. However, there were
no differences in psychological distress between SIBO+ and SIBO− patients. Therefore, it is
unlikely that psychological distress could mediate the association between SIBO and bowel
symptoms.
We anticipated that SIBO+ IBS patients might have lower pain thresholds than IBS- patients
because SIBO is a type of bacterial infection, and bacterial infections that produce
inflammation have been shown to lower sensory thresholds(29). However, our analysis
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showed an opposite trend: SIBO+ IBS patients tend to have higher AML pain thresholds
compared to SIBO− IBS patients. (The AML pain and urge thresholds of both SIBO+ and
SIBO− IBS were significantly lower than HC).
Data have been inconsistent as to whether IBS patients have more phasic contractions than
HC under baseline conditions (i.e., fasting and no stimulation by distention, stress, or
exogenous hormones): there have been reports that IBS patients show more baseline
motility(30), less motility(31), and about the same amount(32) compared to HC. We found
no difference when comparing HC to either SIBO+ or SIBO− IBS patients.
Sustained intraluminal distension by a balloon simulates physiological distension of the
colon by fecal material or gas. We observed an increase in phasic motility in response to this
distension stimulus in both HC and IBS patients with a significantly greater increase in IBS
patients as compared to HC. This is consistent with our previous observations and defines
the “hyper-reactivity” characteristic of IBS patients(33),(34). However, SIBO+ and SIBO−
patients showed similar increases in phasic contractions in response to intraluminal
distension. This response is reversible, with MI returning to baseline when the distending
stimulus is removed in SIBO+, SIBO− IBS as well as HC.
Eating also stimulates an increase in the MI in both HC and IBS, as has been shown by other
studies(35). However, there were no differences in the post-meal MI increase between our
IBS patients and HC, or between SIBO+ and SIBO− IBS patients.
A third goal of our study was to compare methane producers to hydrogen producers.
Methane production is limited to only a few species of bacteria, and two of these
methanogens, Methanobrevibacter smithii and Methanobacterium ruminatum, are only
found in the left colon, which is the major site of methane production. Other anaerobic
species, Bacteroides and Clostridium, can also liberate methane and could easily be part of
the small intestinal flora. We showed a 19% prevalence of PMP in our SIBO+ IBS
population. There were no IBS-D patients in the PMP subgroup, and most PMP patients had
IBS-C. We also found that PMP patients were more likely to report hard/lumpy stools and
stools less often than 3/week. This is in accordance with the emerging concept of methane
production in SIBO, and its subjective as well as objective association with constipation(28).
Methane has been shown to be associated with increased numbers of small intestinal non-
propagating contractions in animal studies(8). Increased numbers of non-propagating
contractions and/or decreased numbers of migrating motor complexes, which normally
sweep bacteria and food residues out of the small intestine during the inter-digestive period,
could permit bacterial overgrowth to occur in the small intestine(36). Our data support the
observations reported in animals by showing higher baseline colonic phasic contractions
(which are primarily non-propagating contractions) in PMP. This would predispose patients
towards further bacterial overgrowth. Further research is needed to characterize the small
intestinal and colonic motility of these different gas producers and their association with
clinical symptoms and predominant bowel patterns.
Our data also show that PMP patients have higher AML urge thresholds than PHP or SIBO−
IBS subjects. This is a novel finding. The pain thresholds of PHP and PMP were, however,
similar to each other.
There was no significant correlation between peak hydrogen and/or methane production
during the HBT, and the IBS-SS or its subscales. This further suggests that IBS and SIBO
are independent dimensions, and those individuals producing more gas do not as a group
have greater severity of IBS symptoms.
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There has been a significant controversy regarding the prevalence of SIBO in IBS, the
means of testing it and its importance in the overall symptomatology of IBS patients.
Pimentel et al proposed diagnosing SIBO by means of the lactulose HBT and reported
positive tests in 78-84% of patients with IBS. However, more recent reports using jejunal
cultures found SIBO in only 4% of the IBS population and detected no differences from a
HC population(37). Lack of uniformity in the tests used to diagnose SIBO has led to
significant anxiety around the whole topic. Our results looking at demographic,
symptomatic, psychological and physiologic parameters have failed to reveal any real
suggestion that SIBO+ individuals are distinct, thereby, supporting the notion that SIBO in
IBS is either an artifact of testing or an epiphenomenon. The methane-IBS C association
holds up and is the likely explanation for any trends towards differences between SIBO+
and SIBO− individuals. It becomes important to understand and correctly diagnose SIBO to
prevent exposure to unnecessary antibiotic therapy which often can be a cause of
perpetuation of gastrointestinal symptoms.
Study limitations
This study has limitations: There can be alternative explanations for a positive HBT other
than SIBO. Poor adherence to the breath testing protocol, especially dietary and smoking
restrictions prior to the test, can lead to high baseline breath hydrogen levels (38). Forty-
eight percent of positive tests in our study were due to high baseline levels. In addition, the
sucrose HBT may rarely give false positive peaks because sucrose is broken down into
glucose and fructose, and it is possible for either sucrose or fructose to give rise to a second,
colonic peak in hydrogen or methane if it passes through the small intestine unabsorbed.
However, only 3 of 58 SIBO+ patients in our study showed a delayed (>60 min) rise in
hydrogen or methane followed by a second peak. Thus, the sucrose HBT appears to be
significantly more sensitive and specific for detection of SIBO in the proximal small
intestine than is the lactulose HBT. A second limitation is that the use of an invasive test
protocol (e.g., barostat testing) may have biased recruitment, as is suggested by the
relatively young age of our sample. However, there is no reason to believe the association
between SIBO and IBS differs in young vs. older patients. Thirdly, the physiologic testing
was done in colon and was not designed to define effects of SIBO, but rather, to seek for
evidence of overall differences; it is possible that SIBO is related more to motility changes
in the small intestine than to motility changes in the colon. Further research on the link
between SIBO and small intestinal motility is needed.
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Table 1





SIBO (n=52) Non-SIBO (n=106)
Age (yr) 32.73±1.50 36.59±1.16 37.21±2.18
Gender
Female 44 89 26
Male 8 17 8
Race
White 38 79 17
Nonwhite 14 27 17
IBS Subtype
 IBS-D 16 31 -
 IBS-C 16 27 -
 IBS-M 20 48 -
IBS-SS
 Overall 272.94±13.88** 278.45±9.58** 25.54±8.6
 Pain severity 42.78±3.65** 49.03±2.53** 4.11±2.09
 Pain Frequency 4.67±0.37** 4.78±0.23** 0.42±0.20
 Distension 46.84±4.37** 47.43±2.94** 2.87±1.34
 Interference 55.48±4.22** 58.07±2.78** 2.44±1.64
 Bowel dissatisfaction 18.90±3.10** 24.23±2.49** 83.67±5.18
 QOL 69.72±2.55** 69.23±2.00** 99.11±0.49
RPSQ-Somatization 11.10±0.62** 10.5±0.47** 4.70±0.72
Catastrophizing 7.60±0.94** 7.30±0.70** 2.25±0.69
BSI-18
 Global Severity 54.53±1.24** ^ 51.77±0.84** 41.70±1.37
 Somatization 55.77±0.98** ^ 53.29±0.78** 44.24±1.07
 Depression 52.46±1.62** 51.20±1.04** 45.82±1.29
 Anxiety 52.82±1.44** 50.31±0.88** 42.72±1.08






p<0.01, compared with controls.
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^
p<0.1 compared with Non-SIBO. SIBO: Small intestinal bacterial overgrowth, IBS-SS: IBS severity scale, RPSQ-Somatization: Recent physician
symptom questionnaire somatization, BSI-18: Brief Symptom Index 18.
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Table 2
Sensory thresholds and colonic motility responses








 Baseline 361.61±37.87 § 301.45±20.97 264.63±30.58
 Distension 987.22±114.02** 943.13±89.59* 577.98±71.65
 Recovery 463.31±48.90* 469.61±49.19§ 316.45±28.14
 Post meal 505±47.43 474.99±30.37 476.16±54.38
 Reactivity 625.61±113.48* 642.87±84.41* 313.34±75.46






p<0.01, compared with controls.
^
p<0.1 compared with Non-SIBO. SIBO: Small intestinal bacterial overgrowth.
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Table 3








 IBS-D 16 0 31
 IBS-C 10 6 27
 IBS-M 16 4 48
IBS SS
 Overall 269.35±13.61 288.00±45.83 278.45±9.58
 Pain severity 40.47±3.61^ 52.50±11.45 49.03±2.53
 Pain frequency 4.55±0.40 5.20±0.99 4.78±0.23
 Distension 46.33±4.59 49.00±12.60 47.43±2.94
 Interference 55.35±4.49 56.00±11.82 58.07±2.78
 Bowel dissatisfaction 18.28±3.03 21.50±10.30 24.23±2.49
QOL 70.51±2.67 66.43±7.29 69.23±2.00
Data are shown as mean ± SEM.
^
p<0.1 compared with Non-SIBO. PHP: Predominant hydrogen producers, PMP: Predominant methane producers, SIBO: Small intestinal bacterial
overgrowth, IBS (D-Diarrhea, C-Constipation, M-Mixed), QOL: Quality of life.
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Table 4
Sensory thresholds and colonic motility responses of PHPs & PMPs






19.54±1.79 28.44±4.27 *^ 18.27±1.24
Motility Index
 Baseline 337.79±45.03 461.64±45.85* 301.45±20.97
 Distension 926.05±110.57 1244.14±374.28 943.13±89.59
 Recovery 463.31±57.21 463.32±88.47 469.61±49.19
 Post meal 497.96±56.13 536.43±78.78 474.99±30.37
 Reactivity 588.26±113.37 782.50±360.78 642.87±84.41






p<0.01, compared with non-SIBO.
^
p<0.1 compared with PHP-SIBO. PHP: Predominant hydrogen producers, PMP: Predominant methane producers, SIBO: Small intestinal bacterial
overgrowth.
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Table 5
Subjective bowel patterns of PHPs & PMPs
PHP (SIBO-IBS) PMP (SIBO-IBS) Non-SIBO IBS
Less then 3 bowel movements in a week (0-2) 0.36±0.07 0.70±0.15 § 0.39±0.04
More then 3 bowel movements in a week (≥4) 0.40±0.07 0.40±0.16 0.47±0.04
Hard and lumpy stools 0.52±0.07 0.90±0.10* 0.53±0.04
Loose, mushy & watery stools 0.71±0.07 0.50±0.16 0.71±0.04






p<0.01, compared with non-SIBO and PHP-SIBO. PHP: Predominant hydrogen producers, PMP: Predominant methane producers, SIBO: Small
intestinal bacterial overgrowth.
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